Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: A randomized crossover trial-Reference-Cited by-同舟云学术

Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: A randomized crossover trial

Published:2018-10-14 Issue:2 Volume:21 Page:349-356
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Moser Othmar¹²^ORCID,Eckstein Max L.¹²,Mueller Alexander³⁴,Birnbaumer Philipp³,Aberer Felix⁵^ORCID,Koehler Gerd⁵,Sourij Caren⁵,Kojzar Harald⁵,Holler Peter⁴,Simi Helmut⁴,Pferschy Peter⁵,Dietz Pavel⁶⁷,Bracken Richard M.¹²^ORCID,Hofmann Peter³,Sourij Harald⁵

Affiliation:

1. Diabetes Research Group, Medical School; Swansea University; Swansea UK

2. Applied Sport, Technology, Exercise and Medicine Research Centre (A-STEM), College of Engineering; Swansea University; Swansea UK

3. Exercise Physiology, Training and Training Therapy Research Group, Institute of Sports Science; University of Graz; Graz Austria

4. Sport Science Laboratory, Institute of Health and Tourism Management; FH Joanneum University of Applied Science; Bad Gleichenberg Austria

5. Division of Endocrinology and Diabetology, Department of Internal Medicine; Medical University of Graz; Graz Austria

6. Department of Physical Activity and Public Health, Institute of Sports Science; University of Graz; Graz Austria

7. Institute of Occupational, Social and Environmental Medicine; University Medical Centre of the University of Mainz; Mainz Germany

Funder

Novo Nordisk, Austria

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13534/fullpdf

Reference32 articles.

1. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN(®) Basal-Bolus type 1): 2-year results of a randomized clinical trial;Bode;Diabet Med,2013

2. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes;Heise;Diabetes Obes Metab,2012

3. Clinical use of insulin degludec;Vora;Diabetes Res Clin Pract,2015

5. Exercise management in type 1 diabetes: a consensus statement;Riddell;Lancet Diabetes Endocrinol,2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No insulin degludec dose adjustment required after aerobic exercise for people with type 1 diabetes: the ADREM study;Diabetologia;2023-03-07

2. Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study);Diabetes Technology & Therapeutics;2023-03-01

3. Metabolic and physiological responses to graded exercise testing in individuals with type 1 diabetes using insulin pump therapy;Diabetes, Obesity and Metabolism;2023-01-03

4. Exercise in adults with type 1 diabetes mellitus;Nature Reviews Endocrinology;2022-10-31

5. Sport und Glukosemetabolismus bei Typ-1-Diabetes;Die Diabetologie;2022-10-07